Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zetomipzomib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kezar Life Sciences Reports Positive Portola Trial Safety Review
    Kezar Life Sciences Reports Positive Portola Trial Safety Review

    17 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241017004238/en

    BUSINESSWIRE
    17 Oct 2024
    Share Share
    Kezar halts mid-stage lupus study after four deaths
    Kezar halts mid-stage lupus study after four deaths

    01 Oct 2024

    // Zoey Becker FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/kezar-halts-dosing-and-enrollment-key-lupus-study-following-4-patient-deaths

    Zoey Becker FIERCE BIOTECH
    01 Oct 2024
    Share Share
    Kezar Life Sciences Ends Enrollment In Ph2 Trial For Zetomipzomib
    Kezar Life Sciences Ends Enrollment In Ph2 Trial For Zetomipzomib

    30 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240930482248/en

    BUSINESSWIRE
    30 Sep 2024
    Share Share
    Kezar Life Sciences Reports Q2 2024 Results And Business Update
    Kezar Life Sciences Reports Q2 2024 Results And Business Update

    13 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240813917196/en

    BUSINESSWIRE
    13 Aug 2024
    Share Share
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    07 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240607753645/en

    BUSINESSWIRE
    07 Jun 2024
    Share Share
    Kezar Life Sciences Q1 2024 Financials, Business Update
    Kezar Life Sciences Q1 2024 Financials, Business Update

    09 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240509839405/en

    BUSINESSWIRE
    09 May 2024
    Share Share